Washington, D.C. (May 9, 2017) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement regarding the confirmation of Dr. Scott Gottlieb as Commissioner of the Food and Drug Administration (FDA):
“BIO congratulates Dr. Scott Gottlieb on his confirmation as Commissioner of the FDA, a position for which he is eminently qualified and which carries immense responsibility in protecting and promoting the health of all Americans.
“The opportunities facing the agency today are tremendous. We are confident that Dr. Gottlieb’s confirmation will provide the agency with the stability and leadership needed to fully harness the tools of modern drug development and to better incorporate patients’ perspectives into the agency’s regulatory processes.
“We look forward to working with Dr. Gottlieb to ensure that the FDA has the necessary staff, resources, and flexibility required to keep pace with the marvelous advances taking place in the fields of biomedical, agricultural, and animal biotechnology.”
About BIO
BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org.
Upcoming BIO Events
June 19-22, 2017 | BIO World Congress on Industrial Biotechnology July 23-26, 2017 |
###